Genomic Analysis of Circulating Tumor Cells at the Single-Cell Level.


Journal

The Journal of molecular diagnostics : JMD
ISSN: 1943-7811
Titre abrégé: J Mol Diagn
Pays: United States
ID NLM: 100893612

Informations de publication

Date de publication:
06 2020
Historique:
received: 06 09 2019
revised: 20 12 2019
accepted: 28 02 2020
pubmed: 6 4 2020
medline: 31 7 2021
entrez: 6 4 2020
Statut: ppublish

Résumé

Circulating tumor cells (CTCs) have a great potential for noninvasive diagnosis and real-time monitoring of cancer. A comprehensive evaluation of four whole genome amplification (WGA)/next-generation sequencing workflows for genomic analysis of single CTCs, including PCR-based (GenomePlex and Ampli1), multiple displacement amplification (Repli-g), and hybrid PCR- and multiple displacement amplification-based [multiple annealing and loop-based amplification cycling (MALBAC)] is reported herein. To demonstrate clinical utilities, copy number variations (CNVs) in single CTCs isolated from four patients with squamous non-small-cell lung cancer were profiled. Results indicate that MALBAC and Repli-g WGA have significantly broader genomic coverage compared with GenomePlex and Ampli1. Furthermore, MALBAC coupled with low-pass whole genome sequencing has better coverage breadth, uniformity, and reproducibility and is superior to Repli-g for genome-wide CNV profiling and detecting focal oncogenic amplifications. For mutation analysis, none of the WGA methods were found to achieve sufficient sensitivity and specificity by whole exome sequencing. Finally, profiling of single CTCs from patients with non-small-cell lung cancer revealed potentially clinically relevant CNVs. In conclusion, MALBAC WGA coupled with low-pass whole genome sequencing is a robust workflow for genome-wide CNV profiling at single-cell level and has great potential to be applied in clinical investigations. Nevertheless, data suggest that none of the evaluated single-cell sequencing workflows can reach sufficient sensitivity or specificity for mutation detection required for clinical applications.

Identifiants

pubmed: 32247862
pii: S1525-1578(20)30075-1
doi: 10.1016/j.jmoldx.2020.02.013
pmc: PMC8351127
pii:
doi:

Types de publication

Comparative Study Evaluation Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

770-781

Subventions

Organisme : NIGMS NIH HHS
ID : P50 GM021700
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM101401
Pays : United States

Informations de copyright

Copyright © 2020 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Références

EMBO Mol Med. 2014 Oct 30;6(11):1371-86
pubmed: 25358515
Science. 2012 Dec 21;338(6114):1622-6
pubmed: 23258894
Nat Rev Cancer. 2011 May;11(5):312
pubmed: 21508964
Nat Rev Genet. 2016 Mar;17(3):175-88
pubmed: 26806412
Nucleic Acids Res. 2001 Jan 1;29(1):308-11
pubmed: 11125122
Cancer Discov. 2012 Nov;2(11):995-1003
pubmed: 23093251
Genome Res. 2017 Aug;27(8):1312-1322
pubmed: 28487279
Nat Med. 2014 Aug;20(8):897-903
pubmed: 24880617
Cell. 2012 Mar 2;148(5):873-85
pubmed: 22385957
Fly (Austin). 2012 Apr-Jun;6(2):80-92
pubmed: 22728672
Clin Cancer Res. 2019 Apr 1;25(7):2254-2263
pubmed: 30617129
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Genome Med. 2013 Aug 23;5(8):73
pubmed: 23998943
Sci Rep. 2018 Mar 21;8(1):4963
pubmed: 29563514
Sci Rep. 2017 Jun 13;7(1):3422
pubmed: 28611458
Clin Cancer Res. 2017 Jan 1;23(1):88-96
pubmed: 27334837
PLoS One. 2015 Aug 24;10(8):e0135007
pubmed: 26302375
Clin Cancer Res. 2016 Mar 15;22(6):1510-9
pubmed: 26671992
PLoS One. 2014 Aug 19;9(8):e105585
pubmed: 25136831
Oncotarget. 2016 May 3;7(18):26107-19
pubmed: 27034166
Clin Cancer Res. 2019 Aug 15;25(16):5049-5060
pubmed: 31113842
PLoS One. 2018 Apr 26;13(4):e0196334
pubmed: 29698522
Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):21083-8
pubmed: 24324171
Nature. 2011 Apr 7;472(7341):90-4
pubmed: 21399628
Nature. 2014 Aug 14;512(7513):155-60
pubmed: 25079324
Clin Cancer Res. 2014 Apr 15;20(8):2080-91
pubmed: 24573554
N Engl J Med. 2008 Jul 24;359(4):366-77
pubmed: 18596266
J Circ Biomark. 2015 May 5;4:3
pubmed: 28936239
Sci Transl Med. 2012 Jul 4;4(141):141ra92
pubmed: 22764208
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Bioinformatics. 2015 Jun 15;31(12):2032-4
pubmed: 25697820
Annu Rev Genomics Hum Genet. 2015;16:79-102
pubmed: 26077818

Auteurs

Shan Lu (S)

Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, California; Stanford Genome Technology Center, Stanford University School of Medicine, Palo Alto, California.

Chia-Jung Chang (CJ)

Stanford Genome Technology Center, Stanford University School of Medicine, Palo Alto, California.

Yinghui Guan (Y)

Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, California.

Edith Szafer-Glusman (E)

Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, California.

Elizabeth Punnoose (E)

Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, California.

An Do (A)

Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, California.

Becky Suttmann (B)

Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, California.

Ross Gagnon (R)

Division of Expression Analysis Genomics, Q2 Solutions, Morrisville, North Carolina.

Angel Rodriguez (A)

Department of Translational Research, Epic Sciences Inc., San Diego, California.

Mark Landers (M)

Department of Translational Research, Epic Sciences Inc., San Diego, California.

Jill Spoerke (J)

Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, California.

Mark R Lackner (MR)

Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, California.

Wenzhong Xiao (W)

Stanford Genome Technology Center, Stanford University School of Medicine, Palo Alto, California. Electronic address: wzxiao@stanford.edu.

Yulei Wang (Y)

Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, California. Electronic address: wang.yulei@gene.com.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH